Abstract:The current 'fixed-dosage strategy' approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug's distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta (2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and licensed drugs.

Measuring Pharmacogene Variant Function at Scale Using Multiplexed Assays.

Multiplexed assays of variant effects contribute to a growing genotype–phenotype atlas

Principles for the Post-Gwas Functional Characterisation of Risk Loci

Polymorphisms Affecting Gene Transcription and Mrna Processing in Pharmacogenetic Candidate Genes: Detection Through Allelic Expression Imbalance in Human Target Tissues

Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project

Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population

Integrated multiplexed assays of variant effect reveal determinants of catechol-O-methyltransferase gene expression

The use of single-nucleotide polymorphism maps in pharmacogenomics

Massively parallel characterization of CYP2C9 variant enzyme activity and abundance

Leveraging in Vitro Models for Clinically Relevant Rare CYP2D6 Variants in Pharmacogenomics

Functional Assays to Screen and Dissect Genomic Hits: Doubling Down on the National Investment in Genomic Research

Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing

Frequency of pharmacogenomic variation and medication exposures among All of Us Participants

Clinical Pharmacogenetics and Potential Application in Personalized Medicine.

Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes

Assessing the function of genetic variants in candidate gene association studies

Screening and validation of double allele-specific binding F-primers for the measurement of antihypertensive pharmacogenomics

[Selection of pharmacogenomic variants and methodology for their use in community pharmacy]

Pharmacogenomics, How to Deal with Different Types of Variants in Next Generation Sequencing Data in the Personalized Medicine Area

Functional dissection of complex and molecular trait variants at single nucleotide resolution

Challenges in constructing genetic instruments for pharmacologic therapies